ARNm stabilisée avec un contenu augmenté en G/C et optimisée pour la translation dans ses zones codées pour la vaccination contre la trypanosomiase, la leishmaniose et la toxoplasmose
VON DER MÜLBE, FLORIAN,PASCOLO, STEVE, DR.,HOERR, INGMAR, DR.
申请号：
EP10007991.2
公开号：
EP2305699B1
申请日:
2002.06.05
申请国别(地区):
EP
年份:
2014
代理人:
摘要：
Pharmaceutical composition (A) contains at least one modified mRNA (I) encoding a biologically active or antigenic (poly)peptide (II), plus a carrier and/or vehicle. Pharmaceutical composition (A) contains at least one modified mRNA (I) encoding a biologically active or antigenic (poly)peptide (II), plus a carrier and/or vehicle. (I) has, in the (II)-coding region: (i) a G/C content higher than that for the wild-type RNA； and/or (ii) at least one codon in the wild-type sequence, for which the tRNA is rare, is replaced by a codon, representing the same amino acid, for which the tRNA is common, but the amino acid sequence encoded by the modified mRNA is the same as that encoded by the wild type. ACTIVITY : Cytostatic； Virucide； Antibacterial； Protozoacide； Nootropic； Neuroprotective； Antiparkinsonian； Immunostimulant. No details of tests for any of these activities are given. MECHANISM OF ACTION : Gene Therapy； Vaccine. No biological data given.
